Kiromic Biopharma, Inc. Shareholder Update: Robbins LLP Reminds Investors of Class Action Against Kiromic Biopharma, Inc. (KRBP)

Kiromic presents itself as a target discovery and gene-editing company that utilizes artificial intelligence to create immunotherapy products.

Metadata
Provider: 
Business Wire, Inc.Business Wire, Inc.
Retrieved on: 
Friday, August 12, 2022
Information
Tags: 
Class Action Lawsuit, Professional Services, Legal, Steps, FDA, Drug Quality and Security Act, Intelligence, Securities Exchange Act of 1934, Kirom Bukhoroi, Patient, Company, NASDAQ, Inc., KRBP, Immunotherapy, Securities Act of 1933, IPO, Complaint, Person, Medical device
Geotags: 
CALIFORNIA, UNITED STATES, NORTH AMERICA
⚠ generated by AI ↴
Organisation: 
ROBBINS LLP
Stock Symbol: 
NASDAQ:KRBP
Summary
Key Points: 
  • Kiromic presents itself as a target discovery and gene-editing company that utilizes artificial intelligence to create immunotherapy products.
  • If you would like more information about Kiromic Biopharma Inc.'s misconduct, click here .
  • Rather than disclosing this information, Kiromic represented that clinical testing was expected to proceed in the third quarter of 2021.
  • A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.


The Class: Shareholder rights law firm Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons or entities that purchased or otherwise acquired Kiromic Biopharma, Inc. (NASDAQ: KRBP) securities pursuant to the Company's July 2021 initial public offering ("IPO"), or between June 25, 2021 and August 13, 2021, for violations of the Securities Act of 1933 and the Securities Exchange Act of 1934. Kiromic presents itself as a target discovery and gene-editing company that utilizes artificial intelligence to create immunotherapy products.

If you would like more information about Kiromic Biopharma Inc.'s misconduct, click here.

What is this Case About: Kiromic Biopharma, Inc. (KRBP) Failed To Disclose In Its Offering Documents That The FDA Had Placed A Clinical Hold On Its Two Drug Candidates

According to the complaint, the offering documents in support of the IPO contained untrue statements of material fact. On June 16 and 17, 2021, the Company received communications from the FDA that the FDA was placing the Company's Investigational New Drug Applications for its two candidates on clinical hold. Rather than disclosing this information, Kiromic represented that clinical testing was expected to proceed in the third quarter of 2021. However, clinical testing did not proceed in the third quarter 2021, nor was it likely given the FDA's imposition of a clinical hold. When a proposed study is placed on clinical hold, no new subjects may be recruited for testing the drug and patients testing the drug must be taken off.

Next Steps: If you acquired shares of Kiromic Biopharma, Inc. pursuant to the Company's IPO or between June 25, 2021 and August 13, 2021, you have until October 4, 2022, to ask the court to appoint you lead plaintiff for the class. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

Contact us to learn more:

Aaron Dumas

(800) 350-6003

[email protected]

Shareholder Information Form

About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. To be notified if a class action against Kiromic Biopharma, Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Copyright: 
Copyright Business Wire 2022